Corrigendum to Annual Report of the Company for the financial year 2024-25.
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures has issued a corrigendum to its FY 2024-25 Annual Report that was originally circulated to shareholders on September 6, 2025. The company is correcting inadvertent errors and omissions across at least 11 sections of the report, including key financial ratios (Net Profit Margin), the Standalone and Consolidated Balance Sheets (reclassifying share warrants into Other Equity), Cash Flow statements, Statement of Changes in Equity, MSMED Act disclosures, Related Party Transactions, analytical ratios, financial instruments, employee benefits, liquidity risk tables, and consolidation adjustments. A revised Annual Report has been attached and filed with both BSE and NSE. The corrigendum was signed by Company Secretary Aravindkumar V on September 23, 2025.
This is a housekeeping correction to the annual report and does not indicate any change in business fundamentals or strategy. Investors should review the revised report for accurate financial figures, especially the Net Profit Margin, share warrant classification, and related party disclosures, but the underlying numbers and outlook for the company remain unchanged.